GlassScriptPhysician profile
Charles Matthew Pesson
NPI 1699778613
$3,430.41
in general payments reported to CMS, 2019-2025
12 companies · $33.60 in 2025
The $33.60 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.58 · 2020: $58.42 · 2022: $14.13 · 2023: $1,300 · 2024: $1,961 · 2025: $33.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,234 · Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,233.66 |
| Food and Beverage | $1,060.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,715.59 | 2023-2024 | Shoulder Implants Fibertak Knotless |
| Legacy Ortho LLC | $1,226.53 | 2023-2024 | |
| Smith+Nephew, INC. | $165.98 | 2024 | Real Intelligence |
| Depuy Synthes Sales INC. | $72.23 | 2019-2024 | Na |
| Pacira Therapeutics, INC. | $63.52 | 2019-2020 | |
| Kyocera Medical Technologies, INC. | $43.14 | 2020 | |
| Ethicon US, LLC | $42.21 | 2024 | Stratafix, Surgicel Nu-Knit, Dermabond |
| Tricoast Surgical Solutions LLC | $33.22 | 2024 | |
| Vericel Corporation | $20.26 | 2023 | Maci |
| Integra Lifesciences Corporation | $17.63 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Pacira Pharmaceuticals Incorporated | $15.97 | 2025 | Zilretta, Iovera, Exparel |
| Alcon Vision LLC | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Pesson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.